SMAD9 Antibody

What is SMAD9 and what is its role in cellular signaling?

SMAD9 (also known as SMAD8 or MAHD6) is a 55-60 kDa R-Group member of the dwarfin/SMAD family of proteins expressed by BMP-responsive cells. It functions as a signal transducer, transmitting information from BMP receptors (BMPR) to the nucleus. Following BMPR activation, SMAD9 undergoes phosphorylation at its C-terminus (specifically at Ser465 and Ser467), which promotes heterodimerization with SMAD4 and subsequent translocation into the nucleus. Inside the nucleus, SMAD9 binds to DNA and participates in gene activation processes . SMAD9 has been characterized as a new type of transcriptional regulator in BMP signaling with distinct properties compared to other SMAD family members .

How does SMAD9 differ structurally and functionally from other SMAD proteins?

SMAD9 shares structural similarities with other R-Smads but exhibits distinct functional characteristics. Structurally, human SMAD9 is 467 amino acids in length, containing a DNA-binding domain (MH1, aa 16-140) and a receptor/transcription factor binding domain (MH2, aa 273-467) . Despite these structural similarities, SMAD9 demonstrates unique functional properties. Its transcriptional activity is significantly lower than that of SMAD1 or SMAD5, even though it exhibits greater DNA-binding activity and stronger association with SMAD4 . This functional distinction is primarily attributed to its linker region, which appears to suppress its ability to activate BMP signaling. Unlike other R-Smads, SMAD9 expression increases in response to BMP signaling (similar to inhibitory Smads), and it functions to reduce BMP activity, positioning it as a distinct regulatory element in the BMP-Smad signaling axis .

What are the key applications for SMAD9 antibodies in research?

SMAD9 antibodies serve multiple critical applications in academic research settings. They are extensively used in immunodetection techniques including Western blotting for protein expression quantification, immunohistochemistry (IHC) for localization studies in tissue sections, immunocytochemistry (ICC) for cellular localization, immunoprecipitation (IP) for protein-protein interaction studies, and ELISA for quantitative measurements . Specifically, these antibodies have been successfully employed to detect SMAD9 in various experimental contexts including human cell lines (such as A172 glioblastoma cells), human tissues (such as prostate cancer tissue), and mouse embryonic tissues . This versatility makes SMAD9 antibodies indispensable tools for investigating BMP-Smad signaling pathways, developmental processes, and pathological conditions where these pathways may be dysregulated.

What are the optimal conditions for using SMAD9 antibodies in immunohistochemistry?

When performing immunohistochemistry (IHC) with SMAD9 antibodies, several methodological considerations are crucial for optimal results. For paraffin-embedded sections, heat-induced epitope retrieval using Antigen Retrieval Reagent-Basic is recommended prior to primary antibody incubation. According to validated protocols, SMAD9 antibodies perform optimally at concentrations of 3 μg/mL when incubated overnight at 4°C . For frozen tissue sections, antibody concentrations around 1.7 μg/mL have been demonstrated to be effective .

Visualization systems such as HRP-DAB detection kits have shown excellent results for SMAD9 detection, with counterstaining using hematoxylin providing good contrast. When examining SMAD9 localization, researchers should note that in prostate cancer tissue, specific staining has been observed primarily in nuclei of glandular epithelial cells, while in developmental contexts such as mouse embryos, SMAD9 localization has been detected in developing muscle cells . These experimental parameters should be optimized based on the specific tissue being examined, as SMAD9 expression and localization patterns may vary across different cell and tissue types.

How should researchers design experiments to differentiate between SMAD9 and other closely related SMAD proteins?

Designing experiments to specifically detect SMAD9 while avoiding cross-reactivity with similar SMAD proteins requires careful consideration of antibody selection and experimental controls. Since SMAD9 shares significant homology with SMAD1 and SMAD5, researchers should select antibodies that target unique regions of SMAD9. Antibodies targeting the internal region of SMAD9, such as those raised against the peptide sequence HSEPLMPHNATYPD, have demonstrated specificity without cross-reacting with SMAD1 and SMAD5 .

A robust experimental approach should incorporate multiple validations. First, perform side-by-side comparison experiments using antibodies specific to each SMAD protein. Second, include siRNA knockdown controls for SMAD9 to confirm specificity of antibody binding. Third, consider using recombinant SMAD proteins (SMAD1, SMAD5, and SMAD9) as positive and negative controls in Western blots to assess cross-reactivity. Finally, when studying transcriptional activities, combine protein detection methods with functional assays such as reporter gene assays (e.g., Id1WT4F-luc) that can distinguish between the activities of different SMAD proteins based on their distinct transcriptional properties .

What are the recommended protocols for detecting SMAD9 phosphorylation in BMP-stimulated cells?

Detection of SMAD9 phosphorylation requires specific methodological approaches that account for the kinetics of BMP signaling. For optimal results, researchers should consider the following protocol:

• Cell stimulation: Treat cells with BMP-4 (typically 10-50 ng/mL) for periods ranging from 15 minutes to 1 hour for phosphorylation studies. Include a control group treated with BMP receptor kinase inhibitors such as LDN-193189 to confirm specificity.

• Lysis conditions: Use phosphorylation-preserving lysis buffers containing phosphatase inhibitors (sodium fluoride, sodium orthovanadate, and β-glycerophosphate) to prevent dephosphorylation during sample preparation.

• Antibody selection: Utilize phospho-specific antibodies that recognize the phosphorylated Ser465/467 residues in the C-terminus of SMAD9, which are critical for its activation.

• Validation: Confirm phosphorylation specificity by comparing results with constitutively active BMPR-IA experiments, as SMAD9 phosphorylation occurs following BMP receptor activation .

• Analysis: When interpreting results, note that while SMAD9 gets phosphorylated similarly to other R-Smads, its functional consequences differ, as phosphorylated SMAD9 does not inhibit the phosphorylation of SMAD1 .

This methodological approach allows researchers to effectively track SMAD9 activation in response to BMP signaling while distinguishing its unique regulatory properties from other SMAD proteins.

How can researchers investigate the inhibitory mechanisms of SMAD9 on BMP signaling compared to classical inhibitory SMADs?

Investigating SMAD9's unique inhibitory mechanisms requires sophisticated experimental approaches that distinguish it from classical inhibitory SMADs (I-SMADs). A comprehensive methodology should include:

• Comparative reporter assay analysis: Utilize BMP-responsive luciferase reporters (such as Id1WT4F-luc) to quantitatively compare inhibitory effects of SMAD9 versus SMAD6/SMAD7 in response to BMP-4 stimulation or constitutively active BMPR-IA expression . This approach reveals that while all three inhibit BMP signaling, their mechanisms differ substantially.

• Receptor interaction studies: Perform co-immunoprecipitation experiments to assess whether SMAD9 interacts with type I receptors like classical I-SMADs. Unlike SMAD6/SMAD7, SMAD9 does not prevent R-SMAD phosphorylation at the receptor level, indicating a distinct inhibitory mechanism .

• DNA-binding analysis: Conduct DNA pull-down assays using BMP-responsive elements (BREs) to determine if SMAD9 competes with other R-SMADs for DNA binding. The evidence shows SMAD9 exhibits stronger DNA binding than SMAD1, even in the absence of SMAD4, suggesting a competitive inhibition mechanism at the DNA level .

• SMAD complex formation investigation: Examine complex formation between SMAD9 and other R-SMADs through co-immunoprecipitation followed by DNA-binding assays. Research has demonstrated that SMAD9 forms complexes with SMAD1 and binds to DNA, but subsequently suppresses transcription of target genes .

• Transcriptional activity analysis: Use chimeric constructs exchanging domains between SMAD9 and other R-SMADs to identify that the linker region of SMAD9 is primarily responsible for its reduced transcriptional activation capacity .

These methodological approaches collectively enable researchers to characterize SMAD9 as a distinct type of transcriptional regulator that inhibits BMP signaling downstream of receptor activation, unlike classical I-SMADs that act at the receptor level.

What techniques are most effective for studying SMAD9-SMAD1 complex formation and its functional consequences?

Investigating SMAD9-SMAD1 complex formation and its functional implications requires a multi-faceted methodological approach:

• Sequential Co-immunoprecipitation and DNA-binding assays: This powerful technique involves first co-immunoprecipitating FLAG-tagged SMAD9 with Myc-tagged SMAD1 using anti-FLAG antibodies, eluting the complexes with FLAG peptide, and then performing DNA pull-down assays with BMP-responsive elements (BREs). This approach has revealed that SMAD9-SMAD1 complexes can bind to BREs, providing direct evidence for a mechanism where SMAD9 exerts its inhibitory effects after DNA binding .

• SMAD4 knockdown experiments: Using siRNA-mediated SMAD4 knockdown followed by co-immunoprecipitation reveals that SMAD9-SMAD1 complexes form independently of SMAD4, distinguishing this interaction from classical SMAD complex formation .

• Chromatin immunoprecipitation (ChIP): ChIP assays at BMP target gene promoters can determine if SMAD9-SMAD1 complexes recruit different transcriptional co-factors compared to SMAD1-SMAD4 complexes, explaining their distinct transcriptional outputs.

• Domain swap experiments: Creating chimeric constructs that exchange domains between SMAD1 and SMAD9 (particularly focusing on the linker region) helps identify the specific structural elements responsible for the inhibitory function of SMAD9 in these complexes .

• Functional readouts: Combining complex analysis with reporter gene assays (Id1WT4F-luc) and endogenous target gene expression analysis (e.g., Osterix) provides a comprehensive understanding of how SMAD9-SMAD1 complexes affect transcriptional outcomes compared to other SMAD complexes .

These methodological approaches collectively demonstrate that SMAD9 forms complexes with SMAD1 that bind DNA but suppress transcription, representing a novel regulatory mechanism in BMP signaling distinct from both classic R-SMADs and I-SMADs.

How can researchers effectively use SMAD9 antibodies to track dynamic changes in SMAD9 expression during embryonic development?

Tracking dynamic changes in SMAD9 expression during embryonic development requires specialized methodological approaches that account for temporal and spatial variations:

• Developmental time-course analysis: Quantitative RT-PCR using carefully selected reference genes reveals that SMAD9 mRNA levels sharply decrease between embryonic days E7.0 and E11.0 in mouse embryos, similar to SMAD6 and SMAD7 but unlike SMAD1, SMAD5, or SMAD4 . This temporal expression pattern suggests a developmentally regulated role for SMAD9.

• Immunohistochemical mapping: For spatial localization, immunohistochemistry on frozen embryonic tissue sections using SMAD9-specific antibodies at optimized concentrations (approximately 1.7 μg/mL) reveals cell type-specific expression patterns. In mouse embryos at 13 d.p.c., SMAD9 has been specifically detected in developing muscle cells .

• Co-localization studies: Dual immunofluorescence staining combining SMAD9 antibodies with markers for specific cell lineages or developmental processes helps correlate SMAD9 expression with particular developmental events.

• BMP signaling perturbation: Analyzing SMAD9 expression changes in response to experimental manipulation of BMP signaling (using BMP ligands or inhibitors) during specific developmental windows provides insight into the regulatory relationships in vivo.

• Conditional genetic approaches: Combining immunodetection with conditional knockout or overexpression models allows for assessment of how SMAD9 expression changes relate to developmental phenotypes.

When interpreting developmental expression data, researchers should note that SMAD9's expression pattern resembles that of inhibitory SMADs rather than other R-SMADs, supporting its proposed function as a specialized transcriptional regulator in BMP signaling during embryogenesis .

What are common challenges in SMAD9 antibody specificity and how can researchers address them?

Researchers frequently encounter several specificity challenges when working with SMAD9 antibodies, each requiring specific methodological solutions:

• Cross-reactivity with SMAD1 and SMAD5: Due to high sequence homology among these R-SMADs, antibodies may bind to multiple SMAD proteins. To address this issue:

  • Select antibodies targeting unique regions, such as those raised against the internal region peptide sequence HSEPLMPHNATYPD that has demonstrated specificity without cross-reacting with SMAD1 and SMAD5 .

  • Validate antibody specificity using overexpression systems with each SMAD protein individually.

  • Perform parallel knockdown experiments for SMAD1, SMAD5, and SMAD9 to confirm signal specificity.

• Variable antibody performance across applications: Some SMAD9 antibodies work well for certain applications but poorly for others. To mitigate this challenge:

  • Validate each antibody for specific applications rather than assuming cross-application functionality.

  • For Western blotting, optimize blocking conditions (5% non-fat milk versus BSA) and antibody concentrations.

  • For immunohistochemistry, compare different antigen retrieval methods, as SMAD9 detection in paraffin-embedded tissues typically requires heat-induced epitope retrieval .

• Detection of splice variants: Human SMAD9 has a documented splice form showing deletion of amino acids 224-260 . To ensure comprehensive detection:

  • Use antibodies targeting conserved regions present in all known splice variants.

  • When possible, employ multiple antibodies targeting different epitopes.

• Low endogenous expression levels: SMAD9 protein abundance is often lower than that of SMAD1 , creating detection challenges. Recommended approaches include:

  • Using more sensitive detection methods such as chemiluminescent substrates with longer exposure times for Western blots.

  • Enriching the target protein through immunoprecipitation before detection.

  • Considering BMP stimulation of cells, as SMAD9 protein levels increase 24 hours after BMP stimulation .

These methodological refinements significantly improve the reliability of SMAD9 antibody-based detection across experimental contexts.

How should researchers interpret apparently contradictory data regarding SMAD9 function as both an R-SMAD and a BMP signaling inhibitor?

The dual nature of SMAD9 as both an R-SMAD (structurally) and a BMP signaling inhibitor (functionally) creates apparent contradictions that require careful methodological consideration and interpretation:

• Context-dependent analysis: SMAD9 exhibits receptor-activated SMAD characteristics (phosphorylation by BMP receptors, SMAD4 interaction, DNA binding) while simultaneously functioning as an inhibitor. When interpreting experimental results, researchers should separately evaluate:

  • Molecular events (phosphorylation, complex formation, DNA binding)

  • Functional outcomes (transcriptional activity, target gene expression)

• Comparison with defined controls: Always include parallel experiments with classical R-SMADs (SMAD1/SMAD5) and I-SMADs (SMAD6/SMAD7) to position SMAD9's activity within the spectrum of SMAD functions. Research has shown that unlike I-SMADs, SMAD9 does not inhibit type I receptor kinase but suppresses constitutively active SMAD1 DVD .

• Domain-specific functional assessment: Utilize chimeric constructs exchanging domains between SMAD9 and other SMADs to identify which regions confer specific properties. Studies have demonstrated that the linker region of SMAD9 is primarily responsible for its reduced transcriptional activation capacity .

• Temporal considerations: SMAD9 expression increases in response to BMP signaling similar to inhibitory SMADs , creating a negative feedback loop. Therefore, early versus late effects should be distinguished in experimental designs.

• Quantitative pathway analysis: Use reporter gene assays with BMP-responsive elements (Id1WT4F-luc) to quantitatively assess the net effect of SMAD9 on pathway activity under varying conditions. Research shows that siRNA knockdown of endogenous SMAD9 in C2C12 cells exposed to BMP-4 increases ALP activity, confirming its net inhibitory function .

This integrated analytical approach recognizes SMAD9 as a unique transcriptional regulator that combines structural features of R-SMADs with functional outcomes resembling I-SMADs, representing a distinct regulatory mechanism in BMP signaling.

What methodological considerations are important when using SMAD9 antibodies to study its subcellular localization under different signaling conditions?

Studying SMAD9 subcellular localization requires specific methodological approaches to capture its dynamic regulation in response to signaling events:

• Signal-dependent fixation timing: SMAD9 undergoes nucleocytoplasmic shuttling following BMP stimulation. Researchers should:

  • Perform time-course experiments with fixation at multiple intervals (15, 30, 60, 120 minutes) after BMP treatment to capture translocation dynamics.

  • Include parallel samples treated with BMP receptor kinase inhibitors (such as LDN-193189) to confirm specificity of the observed localization changes .

• Fixation and permeabilization optimization: The detection of nuclear SMAD9 requires careful attention to:

  • Fixation method: 4% paraformaldehyde provides good preservation of nuclear antigens without excessive cross-linking.

  • Permeabilization conditions: Titrate detergent concentration (0.1-0.5% Triton X-100) to ensure nuclear envelope accessibility without disrupting nuclear architecture.

• Co-localization analysis: To fully understand SMAD9's regulatory mechanisms, researchers should:

  • Perform dual staining with SMAD9 antibodies and SMAD4 or SMAD1 antibodies to assess complex formation in different subcellular compartments.

  • Include nuclear markers (DAPI or specific nuclear protein markers) for precise localization.

  • Quantify nuclear/cytoplasmic ratios across multiple cells using appropriate imaging software.

• Cell-type considerations: SMAD9 localization patterns vary across cell types. Immunofluorescence studies in A172 human glioblastoma cells have shown specific SMAD9 staining localized to the cytoplasm in unstimulated conditions , while in human prostate cancer tissue, nuclear localization in glandular epithelial cells has been observed .

• Validation through fractionation: Complement imaging approaches with biochemical fractionation (separating nuclear and cytoplasmic compartments) followed by Western blotting to provide quantitative assessment of SMAD9 distribution.

These methodological considerations allow researchers to accurately characterize the complex and dynamic subcellular distribution of SMAD9 under varying signaling conditions, providing insight into its unique regulatory functions.

How can researchers apply single-cell analysis techniques to study SMAD9 expression and function in heterogeneous tissues?

Single-cell analysis offers unprecedented opportunities for investigating SMAD9 biology in heterogeneous tissues, requiring specific methodological considerations:

• Single-cell RNA-sequencing (scRNA-seq) approach: When designing scRNA-seq experiments to study SMAD9:

  • Include appropriate developmental timepoints based on known dynamic expression patterns, such as the sharp decrease in SMAD9 expression between E7.0 and E11.0 in mouse embryos .

  • Combine with cell type-specific markers to create expression atlases that correlate SMAD9 expression with specific lineages.

  • Consider BMP stimulation versus inhibition conditions to capture dynamic regulation of SMAD9 and its target genes at single-cell resolution.

• Mass cytometry (CyTOF) implementation: For protein-level analysis:

  • Validate SMAD9 antibodies specifically for metal-conjugation compatibility.

  • Design panels that include both phosphorylated and total SMAD9 detection alongside markers for BMP pathway activity and cell type identification.

  • Analyze data using dimension reduction techniques (t-SNE, UMAP) to identify cell populations with distinct SMAD9 expression or activation patterns.

• Spatial transcriptomics integration: To understand SMAD9 expression in tissue context:

  • Apply techniques such as Visium spatial transcriptomics or MERFISH to map SMAD9 expression patterns relative to anatomical structures.

  • Correlate with immunohistochemistry findings that have shown specific localization patterns, such as SMAD9 expression in developing muscle cells in mouse embryos .

• Live-cell imaging techniques: For dynamic analysis:

  • Develop CRISPR knock-in fluorescent reporters for endogenous SMAD9 to track expression and localization in living cells and tissues.

  • Combine with optogenetic BMP pathway activation to analyze temporal dynamics of SMAD9 regulation.

• Single-cell ChIP-seq or CUT&Tag adaptations: To study SMAD9 chromatin interactions:

  • Apply these techniques to identify cell type-specific binding patterns of SMAD9 compared to other SMAD proteins.

  • Focus analysis on known BMP responsive elements, such as those in the Id1 gene promoter .

These advanced single-cell methodologies will provide unprecedented insight into the cell type-specific functions of SMAD9 and its unique regulatory role in BMP signaling within complex tissues.

What are the methodological considerations for investigating SMAD9's role in pathological contexts such as cancer and fibrosis?

Investigating SMAD9's role in pathological contexts requires specialized methodological approaches that address disease-specific complexities:

• Patient sample analysis strategy:

  • Perform comparative immunohistochemistry on disease and matched control tissues, noting that SMAD9 has been detected in human prostate cancer tissue with specific nuclear localization in glandular epithelial cells .

  • Correlate SMAD9 expression or localization with clinical parameters and patient outcomes using tissue microarrays.

  • Implement multiplex immunofluorescence to simultaneously detect SMAD9 alongside markers of cancer progression or fibrotic activity.

• Disease model systems:

  • Establish SMAD9 knockout or overexpression in relevant cell line models, using techniques like CRISPR/Cas9.

  • Develop conditional SMAD9 transgenic mouse models to study tissue-specific effects in cancer or fibrosis models.

  • Employ organoid culture systems derived from patient samples to study SMAD9 function in a more physiologically relevant context.

• Signaling pathway cross-talk analysis:

  • Investigate interactions between SMAD9-mediated BMP signaling and other pathways implicated in disease progression (such as TGF-β, Wnt, or inflammatory signaling).

  • Use phospho-proteomics to identify disease-specific post-translational modifications of SMAD9 that may alter its function.

  • Perform co-immunoprecipitation studies to identify novel SMAD9 interaction partners specific to pathological conditions.

• Therapeutic targeting assessment:

  • Develop screening systems to identify compounds that modulate SMAD9 activity or expression.

  • Evaluate the effects of existing BMP pathway inhibitors on SMAD9-specific outcomes versus general BMP signaling.

  • Test the impact of SMAD9 modulation on disease-relevant cellular phenotypes such as migration, invasion, or extracellular matrix production.

• Mechanistic validation in primary patient-derived cells:

  • Compare SMAD9 expression, localization, and function between diseased and healthy primary cells.

  • Assess whether the unique inhibitory properties of SMAD9 in BMP signaling are maintained or altered in pathological contexts.

  • Determine if the ratio of SMAD9 to other R-SMADs changes in disease states, potentially shifting the balance of BMP signaling outcomes.

These methodological approaches will advance understanding of SMAD9's specific contributions to disease processes and potentially identify novel therapeutic strategies targeting its unique regulatory functions.

How can researchers design experiments to investigate potential non-canonical functions of SMAD9 beyond BMP signaling?

Investigating potential non-canonical functions of SMAD9 requires innovative experimental designs that look beyond established BMP signaling paradigms:

• Unbiased interaction partner identification:

  • Perform BioID or APEX proximity labeling with SMAD9 as the bait protein to capture transient and stable interactors in living cells.

  • Follow with mass spectrometry to identify novel binding partners outside the canonical BMP pathway.

  • Validate key interactions using co-immunoprecipitation and functional studies.

• Subcellular localization under diverse stimuli:

  • Expose cells to various signaling inputs beyond BMP (including inflammatory cytokines, stress conditions, growth factors) and track SMAD9 localization using immunofluorescence.

  • Focus particularly on cell types where SMAD9 shows distinctive expression patterns, such as glioblastoma cells where cytoplasmic localization has been observed or prostate cancer tissue where nuclear localization has been documented .

  • Complement with biochemical fractionation and Western blotting to quantify redistribution.

• Chromatin association mapping:

  • Perform ChIP-seq for SMAD9 under various stimulation conditions to identify potentially novel DNA binding sites beyond classic BMP-responsive elements.

  • Compare binding patterns with other SMAD proteins to identify SMAD9-specific targets.

  • Integrate with transcriptome analysis to correlate binding with gene expression changes.

• Pathway-specific loss-of-function studies:

  • Design experiments with simultaneous SMAD9 knockdown and specific pathway inhibitors to isolate SMAD9 functions independent of BMP signaling.

  • Utilize CRISPR interference to achieve tissue-specific knockdown in complex model systems.

  • Assess phenotypic outcomes such as differentiation, apoptosis, or migration that may reveal non-canonical functions.

• Domain-specific mutant analysis:

  • Create targeted mutations in specific SMAD9 domains while preserving others to dissect which structural elements participate in non-canonical versus canonical functions.

  • Focus particularly on the linker region, which has been identified as responsible for SMAD9's unique transcriptional properties .

  • Combine with rescue experiments to determine the functional significance of each domain in various cellular contexts.

These methodological approaches will expand our understanding of SMAD9 beyond its established role as a transcriptional regulator in BMP signaling, potentially revealing novel functions relevant to both physiological and pathological processes.